Approaches to the treatment of Graves’ orbitopathy: yesterday, today, tomorrow
DOI:
https://doi.org/10.22141/2309-8147.8.2.2020.209922Keywords:
Graves’ orbitopathy, glucocorticosteroids, radiation therapy, orbital decompression, teprotumumab, computer 3D modelingAbstract
Background. The article highlights the main approaches to the treatment of patients with Graves’ orbitopathy (GO), which remains a topical issue in ophthalmology and endocrinology, as this pathology affects the quality of life, can lead to vision loss, which is a medical and social problem. The purpose of our work was to analyze the literature data on the main approaches to the treatment of patients with Graves’ orbitopathy, which were used in the past, the current guidelines of European Group on Graves’ Orbitopathy (EUGOGO) 2016 and prospects for new researches, to evaluate advantages and disadvantages of each method of treatment. Results. Approaches to the treatment of GO have changed over time due to the development of science and a deeper understanding of the etiology and pathogenesis of this disease. The use of corticosteroids, radiation therapy, surgical treatment are main methods used for the management of patients with GO, but each of them has advantages and disadvantages. Conclusions. EUGOGO 2016 recommends a step-by-step approach to the management of patients with GO, depending on its activity and severity and impact on the quality of life of the patient. At present, the optimal specific method of treatment has not been determined, but the study of the effect of new drugs and the use of computer 3D modeling in the preoperative phase seems quite promising.
References
Kahaly et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur. Thyroid. J. 2018. 7. 167-186. https://doi.org/10.1159/000490384.
Ross D.S., Burch H.B., Cooper D.S. [et al.]. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016. Vol. 26. № 10. P. 1343-1421. doi: 10.1089/thy.2016.0229.
Ткаченко В.І. Аналіз поширеності тиреоїдної патології та захворюваності на неї серед населення Київської області та України за 2007–2017 рр. Міжнародний ендокринологічний журнал. 2018. Т. 14. № 3. С. 279-284. Режим доступу: http://nbuv.gov.ua/UJRN/Mezh_2018_14_3_14
Черенько М.С. Безпечність пульс-терапії глюкокортикоїдними гормонами у лікуванні ендокринної орбітопатії. Клінічна ендокринологія та ендокринна хірургія. 2018. № 3(63). https://doi.org/10.24026/1818-1384.3(63).2018.142675
Smith T.J., Hegedüs L. Graves’ disease. N. Engl. J. Med. 2016 Oct 20. 375(16). 1552-65.
Smith T.J., Janssen J.A.M.J.L. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr. Rev. 2019 Feb 1. 40(1). 236-67.
Tsui S., Naik V., Hoa N. et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J. Immunol. 2008. 181. 4397-4405.
Bahn R.S. Graves’ ophthalmopathy. N. Engl. J. Med. 2010. 362. 726-738.
Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G.J., Marcocci C. et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid. J. 2016 Mar. 5(1). 9-26. doi: 10.1159/000443828.
Tanda M.L., Piantanida E., Liparulo L., Veronesi G., Lai A., Sassi L., Pariani N., Gallo D., Azzolini C., Ferrario M., Bartalena L. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen et a single center. J. Clin. Endocrinol. Metab. 2013. 98. 1443-1449.
Mourits M.P., Koornneef L., Wiersinga W.M., Prummel M.F., Berghout A., van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol. 1989. 73. 639-644.
Graves R.J. Newly observed affection of the thyroid gland in females. London Med. and Surg. J. 1835. 7. 516-7.
Von Basedow K.A. Exophthalmus durch Hypertrophie des Zellgewebes in der Augenhöhle. [Casper’s] Wochenschrift für die gesammte Heilkunde, Berlin, 1840. 6. 197-204; 220-228. Englische Übersetzung in: Ralph Hermon Major (1884–1970): Classic Descriptions of Disease. Springfield, C.C. Thomas, 1932. 2nd edition, 1939; 3rd edition, 1945.
Gerabek W. Enzyklopädie Medizingeschichte, S. 152. 2005; zuletzt eingesehen am 24. März 2008.
Hertz S., Roberts A. Application of radioactive iodine in therapy of Grave’s disease. J. div. 1942. 21(624); zuletzt eingesehen am 10. März 2008.
Bellows J.G. et al. Early clinical results of ACTH and cortisone in treatment of ocular diseases. Arch. Ophth. 1951. 45. 320.
Scheie H.G., Tyner G.S., Buessler J.A., Alfano J.E. Adrenocorticotropic hormone (ACTH) and cortisone in ophthalmology. Arch. Ophth. 1951. 45. 301.
Chandler G.N., Hartfall S.J. Cortisone and ACTH in exophthalmic ophthalmoplegia. Lancet. 1952. 1. 847.
Aterman K., Cope C.L. et al. Cortisone in exophthalmos: report on a therapeutic trial of cortisone and corticotrophin (ACTH) in exophthalmos and exophthalmic ophthalmoplegia, by a Panel Appointed by the Medical Research Council. 1955. 1. 6.
Bruwn J., Coburn J.W., Wigod R.A., Hiss J.M.Jr., Dowling J.T. Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves’ disease. Am. J. Med. 1963 Jun. 34. 786-95. doi: 10.1016/0002-9343(63)90087-1.
Bartalena L., Marcocci C., Bogazzi F., Bruno-Bossio G., Pinchera A. Glucocorticoid therapy of Graves’ ophthalmopathy. Exp. Clin. Endocrinol. 1991. 97. 320-328.
Smith T.J. Dexamethasone regulation of glycosaminoglycan synthesis in cultured human fibroblasts: similar effects of glucocorticoid and thyroid hormone therapy. J. Clin. Invest. 1984. 64. 2157-2163.
Smith T.J., Bahn R.S., Gorman C.A. Hormonal regulation of hyaluronate synthesis in cultured fibroblasts; evidence for differences between retroocular and dermal fibroblasts. J. Clin. Endocrinol. Metab. 1989. 69. 1019-1023.
Bartalena L., Marcocci C., Pinchera A. Treating severe Graves’ ophthalmopathy. Bailliere’s Clin. Endocrinol. Metab. 1997. 11. 521-536.
Prummel M.F., Mourits M.P., Blank L., Berghout A., Koornneef L., Wiersinga W.M. Randomised double-blind trial of prednisone vs. radiotherapy in Graves’ ophthalmopathy. Lancet. 1993. 342. 949-954.
Marino M., Morabito E., Brunetto M.R., Bartalena L., Pinchera A., Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004. 14. 403-406.
Marcocci C., Bartalena L., Panicucci M. et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin. Endocrinol. (Oxf). 1987. 27. 33-42.
Pinchera A., Bartalena L., Chiovato L., Marcocci C. Radiotherapy of Graves’ ophthalmopathy. In: Gorman C.A., Waller R.R., Dyer J.A. (eds) The Eye and Orbit in Thyroid Disease. Raven Press, New York, 1984. P. 301-316 117.
Bartalena L., Marcocci C., Manetti L., Tanda M.L., Dell’Unto E., Rocchi R., Cartei F., Pinchera A. Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid. 1998. 8. 439-441.
Bartalena L., Pinchera A., Marcocci C. Management of Graves’ Ophthalmopathy. Reality and Perspectives Endocrine Reviews. 1 April 2000. Vol. 21. Is. 2. P. 168-199.
Donaldson S.S., Bagshaw M.A., Kriss J.P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 1973. 37. 276-285.
Olivari N. Transpalpebral decompression of endocrine ophthalmopathy (Graves’ disease) by removal of intraorbital fat: experience with 147 operations over 5 years. Plast Reconstr. Surg. 1991. 87. 627-41.
Rootman D.B. Orbital Decompression for Thyroid Eye Disease, Survey of Ophthalmology. 2017. doi: 10.1016/j.survophthal.2017.03.007.
Tooley A.A., Godfrey K.J., Kazim M. Evolution of thyroid eye disease decompression-dysthyroid optic neuropathy. Eye. 2019. 33. 206-211.
Tyler M.A., Zhang C.C., Saini A.T., Yao W.C. Cutting-edge endonasal surgical approaches to thyroid ophthalmopathy. Laryngoscope Investig. Otolaryngol. 2018. 3(2). 100-104. Published 2018 Feb 26. doi: 10.1002/lio2.143.
Sellari-Franceschini S., Dallan I., Bajraktari A. et al. Surgical complications in orbital decompression for Graves’ orbitopathy. Complicanze chirurgiche in pazienti sottoposti a decompressione orbitaria per oftalmopatia di Graves. Acta Otorhinolaryngol. Ital. 2016. 36(4). 265-274. doi: 10.14639/0392-100X-1082.
Leong S.C., Karkos P.D., Macewen C.J. et al. A systematic review of outcomes following surgical decompression for dysthyroid orbitopathy. Laryngoscope. 2009. 119. 1106-15.
Douglas R.S. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond). 2019. 33(2). 183-190. doi: 10.1038/s41433-018-0321-y.
Douglas R.S., Kahaly G.J., Patel A. et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N. Engl. J. Med. 2020. 382(4). 341-352. doi: 10.1056/NEJMoa1910434.
Kamer L. et al. Anatomy-Based Surgical Concepts for Individualized Orbital Decompression Surgery in Graves Orbitopathy. I. Orbital Size and Geometry. Ophthal. Plast. Reconstr. Surg. 2010. Vol. 26. № 5. doi: 10.1097/IOP.0b013e3181c9bb52.
Kamer L. et al. Anatomy-Based Surgical Concepts for Individualized Orbital Decompression Surgery in Graves Orbitopathy. II. Orbital Rim Position and Angulation. Ophthal. Plast. Reconstr. Surg. 2012. Vol. 28. № 4. doi: 10.1097/IOP.0b013e31824ddbfd.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Archive of Ukrainian Ophthalmology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
